Madrigal registers pediatric Phase 2a trial of resmetirom for MASH
New multiple ascending dose study will test resmetirom in children and adolescents ages 6-17 with MASH and liver fibrosis.
Madrigal Pharmaceuticals had one notable registry update this week.
- Madrigal is recruiting for a new Phase 2a trial (NCT07763015) evaluating resmetirom in pediatric patients. The study is a multicenter, open-label, multiple ascending dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of resmetirom in pediatric subjects ages 6-17 years with MASH with fibrosis stage F1-F3.1 The trial has an estimated enrollment of 61 participants, with participants receiving oral resmetirom once daily for approximately 14 days at one of several dose levels.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.